Skip to Content

'
Naveen Pemmaraju, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2005 University of Arkansas for Medical Sciences, Little Rock, AR, MD, Medicine
2001 Tulane University, New Orleans, LA, BS, Cum Laude, Cell and Molecular Biology

Postgraduate Training

7/2008-6/2011 Clinical Fellowship, Hematology and Medical Oncology, MD Anderson Cancer Center, Houston, TX, Waun Ki-Hong, MD
7/2005-6/2008 Clinical Residency, Internal Medicine, Johns Hopkins Hospital, Osler Internal Medicine Program, Baltimore, MD, Myron Weisfeldt, MD

Experience/Service

Administrative Appointments/Responsibilities

Associate Program Director, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Leukemia Fellowship Program, Houston, 2011-present

Other Appointments/Responsibilities

Chief Fellow Housestaff Education, Hematology/Oncology, MD Anderson Cancer Center Fellowship Program, Houston, TX, 2009-2010

Institutional Committee Activities

Member, Interviewing Committee, MD Anderson Hematology/Oncology Fellowship Program, 4/2010

Honors and Awards

2012 M. D. Anderson Apple Award for Excellence in Patient Education, MD Anderson Cancer Center
2011-present Advocacy Leadership Institute, American Society of Hematology
2011 Merit Award, American Society of Clinical Oncology
2010-2011 The Kimberly Patterson Fellowship in Leukemia Research
2010 Celgene 2010 Future Leaders Award for Clinical Research in Hematology, Celgene
2010 Jesse H. Jones Outstanding Teaching Fellow Award, MD Anderson Institutional Scholarship
2005 Elected, Class President and Student Commencement Speaker, University of Arkansas for Medical Sciences
2005 H. Elvin Shuffield, MD Outstanding Medical Leadership Award
2004-2005 Academic Scholarship, Arkansas Blood and Cancer Society
2004-2005 Academic Scholarship, Arkansas Medical Society Alliance AMA Foundation
2004-2005 Outstanding Geriatrics Medical Student, Junior Clerkship Award
2003-2004 George Link Ackerman Academic Medical Scholarship
2002-2003 Academic Medical Scholarship, Inaugural Class of 1957 UAMS Alumni
2000 Outstanding Peer Health Advocate of the Year, Student Crest Leadership Award

Selected Publications

Peer-Reviewed Original Research Articles

1. Ohanian M, Borthakur G, Quintas-Cardama A, Mathisen M, Cortés JE, Estrov Z, Pemmaraju N. Ocular Granulocytic Sarcoma: A Case Report and Literature Review of Ocular Extramedullary Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13(1):93-6, 2/2013. e-Pub 9/2012. PMID: 23017332.
2. Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O'Brien S, Cortes J. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica 97(7):1029-35, 7/2012. e-Pub 1/2012. PMCID: PMC3396674.
3. Pemmaraju N, Munsell MF, Hortobagyi GN, Giordano SH. Retrospective review of male breast cancer patients: analysis of tamoxifen related side effects. Ann Oncol 23(6):1471-4, 6/2012. e-Pub 11/2011. PMCID: PMC3493137.
4. Pemmaraju N, Hamilton JP, Cameron AM, Sisson S, Moliterno AR. Abdominal venous thrombosis presenting in Myeloproliferative neoplasm with JAK2 V617F mutation: a case report. J Med Case Rep 6(1):102, 2012. e-Pub 4/2012. PMCID: PMC3349475.
5. Pemmaraju N, Kantarjian H, Ravandi F, Cortes J. FLT3 inhibitors in the treatment of acute myeloid leukemia: The start of an era? Cancer 117(15):3293-304, 8/2011. e-Pub 2/2011. PMID: 21319142.
6. Stein BL, Williams DM, Wang NY, Rogers O, Isaacs MA, Pemmaraju N, Spivak JL, Moliterno AR. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica 95(7):1090-7, 7/2010. e-Pub 2/2010. PMCID: PMC2895032.
7. Pemmaraju N, Feldman LS. Solifenacin-induced small bowel pseudo-obstruction. J Hosp Med 3(2):176-8, 3/2008. PMID: 18438799.
8. Pemmaraju N, Moliterno AR, Williams DM, Rogers O, Spivak JL. The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. Leukemia 21(10):2210-2, 10/2007. e-Pub 5/2007. PMID: 17507997.
9. Pemmaraju N, Dassopoulos T, Moliterno AR. An absorbing problem. Am J Med 120(3):229-30, 3/2007. PMID: 17349442.

Abstracts

1. Hoehn D, Pemmaraju N, Cortes JE, Wang X, Kanagal-Shamanna R, Dellasala SE, Nazha A, Kantarjian HM, Medeiros LJ, Bueso-Ramos CE. Dasatinib Affects Bone Homeostasis, Independent of Molecular Response, in Patients with Chronic Myelogenous Leukemia (CML). Canadian Academy of Pathology's 101st Annual Meeting, 3/2012.
2. Pemmaraju N, Thomas D, Kantarjian HM, Cortes JE, Manning JT, Medeiros LJ, O'Brien S, Daver NG, Nazha A, Pierce SA, Garcia-Manero G, Jabbour EJ, Faderl S. Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm. ASH Annual Meeting 2012, 2012.
3. Pemmaraju N, Kantarjian HM, Tran KM, Kazmi SM, Kadia TM, Borthakur G, Verstovsek S, O'Brien S, Garcia-Manero G, Estrov Z, Faderl S, Ravandi F, Pierce SA, Cortes JE, Quintas-Cardama A. Cytogenetic and Molecular Characterization of Extramedullary Disease (EMD) in Patients (pts) with Acute Myeloid Leukemia (AML). ASH Annual Meeting 2012, 2012.
4. Pemmaraju N, Kantarjian HM, Cortes JE, Quintas-Cardama A, Pierce SA, Verstovsek S. Incidence and Outcomes of Myeloproliferative Neoplasms (MPN) in Adolescents and Young Adults (AYAs). ASH Annual Meeting 2012, 2012.
5. Pemmaraju N, Kantarjian HM, O'Brien S, Kadia TM, Cortes JE, Borthakur G, Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Quintas-Cardama A, Jabbour EJ, Koller CA, Dellasala SE, Pierce SA, Burton EM, Verstovsek S. Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia. ASH Annual Meeting 2012, 2012.
6. Pemmaraju N, Ravandi F, Rondon G, Giralt S, Chen J, Pierce S, Champlin R, DeLima M, Qazilbash M. Analysis of outcomes in patients (pts) with relapsed/refractory acute promyelocytic leukemia (APL) treated with and without high-dose chemotherapy and hematopoietic stem cell transplantation (HCT). Journal of Clinical Oncology 29(Supl 15):Abstr 6608, 6/2011.
7. Kadia T, Garcia-Manero G, Kantarjian H, Pemmaraju N, Stein K, Teng A, Cortes J. Retrospective analysis of effects of transfusion status on response to decitabine and survival in patients with myelodysplastic syndromes. Journal of Clinical Oncology 29(Supl 15):Abstr 6608, 6/2011.
8. Gushiken F, Vo YD, Xiao L, Kadia T, Cortes JE, Pemmaraju N, Pierce S, Kantarjian H, Borthakur G. Coagulation profile as prognostic indicator in acute myeloid leukemia. American Society of Hematology Annual Meeting 2011, 2011.
9. Takahashi K, Kantarjian H, Pemmaraju N, Borthakur G, Faderl S, Garcia-Manero G, Andreeff M, Pierce S, Ravandi F, Cortes J. FLT3 inhibitors are promising salvage therapy for relapsed or refractory acute myeloid leukemia in patients with FLT3-ITD mutations. American Society of Hematology Annual Meeting 2011, 2011.
10. Pemmaraju N, Kantarjian H, Tanaka MF, O'Brien S, Jabbour E, Quintas-Cardama A, Borthakur G, Ravandi F, Verstovsek S, Burton E, Walker B, Cortes J. Memory impairment in chronic phase chronic myeloid leukemia patients treated with dasatinib tyrosine kinase inhibitor therapy. American Society of Hematology Annual Meeting 2011, 2011.
11. Pemmaraju N, Kantarjian H, Luthra R, O'Brien S, Jabbour E, Quintas-Cardama A, Borthakur G, Ravandi F, Verstovsek S, Burton E, Walker B, Cortes J. Results of a phase II trial of dasatinib as frontline therapy for chronic myeloid leukemia in chronic phase. American Society of Hematology Annual Meeting 2011, 2011.
12. Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O'Brien S, Cortes J. Analysis of outcomes in adolescents and young adults (AYA) with chronic myeloid leukemia (CML) treated with upfront tyrosine kinase inhibitors (TKI). Blood 116(21):Abstr 1234, 11/2010.
13. Pemmaraju N, Kantarjian H, Garcia-Manero G, Faderl S, Ferrajoli A, Borthakur G, Kadia T, Cortes J. Phase I study results of gimatecan in the treatment of myelodysplastic syndrome (MDS). Blood 116(21):Abstr 1883, 11/2010.
14. Pemmaraju N, Kantarjian H, O'Brien S, Verstovsek S, Jabbour E, Quintas-Cardama A, Garcia-Manero G, Borthakur G, Ravandi F, Shan J, Cortes J. Seven-year follow-up data on sequential prospective trials of imatinib 400mg vs 800mg daily schedule for front-line treatment of chronic myeloid leukemia (CML). Blood 116(21):Abstr 3438, 11/2010.
15. Pemmaraju N, Kantarjian H, Faderl S, Garcia-Manero G, Kadia T, Borthakur G, Cortes J, Ravandi Kashani F. Impact of neutropenia on the outcome of decitabine (DAC) treatment in patients (pts) with myelodysplastic syndrome (MDS). Journal of Clinical Oncology 28(Supl 15):Abstr 6605, 6/2010.
16. Pemmaraju N, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Parikh S, Konopleva M, Kornblau S, Andreeff M, O'Brien S, Cortes J. FLT3 inhibitor therapy for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): impact on survival according to FLT3 status. Blood 114:Abstr 1026, 11/2009.
17. Pemmaraju N, Kantarjian H, Ravandi F, O'Brien S, Wierda W, Thomas D, Garcia-Manero G, Borthakur G, Pierce S, Cortes J. Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience. Journal of Clinical Oncology 27(Supl 15):Abstr 7051, 6/2009.
18. Pemmaraju N, Kantarjian H, Ravandi F, O’Brien S, Wierda W, Thomas D, Garcia-Manero G, Borthakur G, Pierce S, Cortes J. Acute myeloid leukemia in adolescents and young adults (AYA): The MD Anderson Cancer Center (MDACC) experience. Blood 112:Abstr 3982, 11/2008.
19. Stein B, Williams D, Rogers O, Isaacs M, Pemmaraju N, Moliterno A. Gender is a phenotypic modifier in the JAK2 V617F-positive MPD. Blood 112:Abstr 1761, 11/2008.

Book Chapters

1. Pemmaraju N, Parikh S, Jabbour E, Kantarjian H, Cortes J. Chronic Myeloid Leukemia. In: MD Anderson Manual of Oncology, 2nd, 2011.

Grant & Contract Support

Title: Ofatumumab as upfront treatment in elderly unfit CLL patients
Funding Source: NCCN - National Comprehensive Cancer Network
Role: Collaborator
Principal Investigator: Ferrajoli A
Duration: 10/10/2011 - 10/31/2015

Last updated: 7/25/2014